Tofacitinib for treating juvenile idiopathic arthritis:  A Fast Track Appraisal. Evidence Review Group Report for the National Institute for Health and Care Excellence

Mark Rodgers; Sahar Sharif; Matthew James Walton; Melissa Harden; Sofia Dias; Lindsay Claxton

Tofacitinib for treating juvenile idiopathic arthritis: A Fast Track Appraisal. Evidence Review Group Report for the National Institute for Health and Care Excellence

Mark Rodgers, Sahar Sharif, Matthew James Walton, Melissa Harden, Sofia Dias, Lindsay Claxton

Centre for Reviews and Dissemination

Research output: Book/Report › Commissioned report

Original language	English
Commissioning body	National Institute for Health Research (NIHR)
Publication status	Published - 2022

Cite this

@book{328cd8049ba84f8d9b8ff44e2fd93d81,

title = "Tofacitinib for treating juvenile idiopathic arthritis: A Fast Track Appraisal. Evidence Review Group Report for the National Institute for Health and Care Excellence",

author = "Mark Rodgers and Sahar Sharif and Walton, {Matthew James} and Melissa Harden and Sofia Dias and Lindsay Claxton",

year = "2022",

language = "English",

}

TY - BOOK

T1 - Tofacitinib for treating juvenile idiopathic arthritis

T2 - A Fast Track Appraisal. Evidence Review Group Report for the National Institute for Health and Care Excellence

AU - Rodgers, Mark

AU - Sharif, Sahar

AU - Walton, Matthew James

AU - Harden, Melissa

AU - Dias, Sofia

AU - Claxton, Lindsay

PY - 2022

Y1 - 2022

UR - https://www.nice.org.uk/guidance/ta735/documents/committee-papers

M3 - Commissioned report

BT - Tofacitinib for treating juvenile idiopathic arthritis

ER -

Tofacitinib for treating juvenile idiopathic arthritis: A Fast Track Appraisal. Evidence Review Group Report for the National Institute for Health and Care Excellence

Other files and links

Cite this